Abstract 5801
Background
Malignant tumors represent a major public health problem in the world and Mexico is not the exception. The development of Population-Based Cancer Registries (PBCR) that collect cancer cases in a determined locality and help evaluate health programs is fundamental. In Mexico there were only a couple of attempts on hospital and histopathological registries, reason why it was decided to implement a PBCR, named as the National Network of Cancer Registries (NNCR).
Methods
During the creation process, support was received from the International Agency of Research in Cancer (IARC), through the Global Initiative for Cancer Registry Development. The NNRC is operated in a central level located in Mexico City, and the cases in the sources of information established are registered in a national registration form composed of 29 variables structured and standardized according to international guidelines. The collection and administration of information is done through a technological system, called RedCancerMX in a mobile and web application hosted on the cloud.
Results
In 2016, the General Health Law was modified to create the National Cancer Registry and in 2017 it was approved. In July 2018 the regulations of the NNCR are published, which establishes the bases for organization, integration and coordination. To the date, the NNCR is active in 8 cities, reaching 10% of national coverage. The process of integration of each city to the NNCR, included a feasibility analysis, validation and training. The process of obtaining data covers subprocesses of collection, validation and authorization carried out by medical specialists. RedCancerMX had integrated 11 validations established by international organizations to guarantee the quality of the information and they are aligned to quality indicators proposed by the IARC: comparability, validity, timeliness and completeness.
Conclusions
In Mexico, the NNCR is already established, which is considered an epidemiological surveillance system with national, active and continuous validity. This NNCR will allow us to determine the incidence of cancer and survival rates in the Mexican population, helping to implement new and better strategies for cancer control.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Instituto Nacional de Cancerología.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1500 - Retrospective evaluation of neutropenic admission events in metastatic or high-risk hormone-sensitive prostate cancer (HSPC) patients having docetaxel chemotherapy upfront or for castrate-resistant prostate cancer (CRPC) in STAMPEDE
Presenter: Harriet Mintz
Session: Poster Display session 3
Resources:
Abstract
3524 - Cabazitaxel For Octogenarian Patients With Metastatic Castration-Resistant Prostate Cancer (MCRPC).
Presenter: Paolo Tralongo
Session: Poster Display session 3
Resources:
Abstract
5637 - External Validation of a Prognostic Score in First-Line Metastastic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: David Lorente
Session: Poster Display session 3
Resources:
Abstract
3228 - Treatment outcomes of 3rd treatment in a real-world metastatic castration resistant prostate cancer (mCRPC) population: results from the Dutch CAPRI-registry
Presenter: Jessica Notohardjo
Session: Poster Display session 3
Resources:
Abstract
4695 - Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion>5%: a propensity score matching analysis from SEER database
Presenter: Junru Chen
Session: Poster Display session 3
Resources:
Abstract
4438 - Multi-institutional evaluation of therapeutic management for oligometastatic cancer prostate recurrence with choline-PET/CT
Presenter: Morgane Guibert-broudic
Session: Poster Display session 3
Resources:
Abstract
4574 - Safety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): a network meta-analysis of randomized controlled trials (RCT)
Presenter: Amelia Altavilla
Session: Poster Display session 3
Resources:
Abstract
3816 - Real-world use of radium-223 for treatment of metastatic castration resistant-prostate cancer (mCRPC): results from the Dutch CAPRI registry
Presenter: Malou Kuppen
Session: Poster Display session 3
Resources:
Abstract
5180 - A phase 2a study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
1067 - Adding ADT to PSMA-PET/CT-guided SBRT for oligometastatic prostate cancer improves distant progression-free survival
Presenter: Carole Mercier
Session: Poster Display session 3
Resources:
Abstract